Impairment of glucose metabolism (in particular insulin resistance and type 2 diabetes mellitus) has been reported in patients who have undergone hematopoietic SCT (HSCT) during childhood, especially those treated with TBI. This pilot study was conducted to determine prevalence of and possible underlying mechanisms for impaired glucose homeostasis in young adults treated with HSCT and TBI and who were not previously known to have diabetes mellitus. A total of 10 subjects (6 males, 4 females) were evaluated. Mean ages were 13.0 ± 1.0 years at the time of TBI and 24.0±1.1 years at the time of this study. Five subjects had laboratory evidence of insulin resistance using the homeostasis model assessment and the quantitative insulin sensitivity check index indices. Two of these subjects had impaired fasting glucose and four had decreased plasma insulin-like growth factor 1 levels. All 10 subjects had evidence of abdominal obesity. Insulin resistance is frequently observed in adult survivors of HSCT treated with TBI in childhood. Underlying mechanisms may include radiation-induced growth hormone deficiency and changes in body composition.
Introduction
Survival rates have improved for many cancers that affect children and adolescents, such that in the United States, today, the overall 5-year survival rate is in excess of 70%. 1 Contemporary therapies for cancer include the use of multimodality therapies (for example, the combination of chemotherapy, radiation and surgery) as well as multiagent chemotherapeutic regimens. Unfortunately, the long-term consequences of exposing young individuals to these therapies are considerable. Endocrine sequelae are present in up to 40% of childhood cancer survivors. 2 Several reports have suggested that patients who have undergone hematopoietic SCT (HSCT) during childhood appear to be at increased risk of developing impaired glucose metabolism, in particular insulin resistance. [3] [4] [5] [6] [7] Although the incidence, natural history and underlying pathogenesis for abnormal glucose homeostasis remain unclear, exposure to TBI, in particular, has emerged consistently as a significant risk factor. 3, 4, 6, 8 This pilot study was conducted to generate preliminary data on the prevalence of and potential mechanisms that may cause impaired glucose homeostasis in young adults treated with TBI and who were not previously diagnosed with diabetes mellitus.
Subjects and methods
The study protocol was approved by the Memorial SloanKettering Cancer Center Institutional Review Board. All study participants provided written informed consent for study participation and release of medical record information.
Subjects
A total of 10 subjects (6 males, 4 females) were recruited from the Long-Term Follow-Up Clinic (LTFUC) at our institution. To be eligible, subjects had to be cancer free for at least 2 years and X18 years of age at the time of the study. They should have been treated at our institution with TBI before 21 years of age and should have completed all cancer treatments at least 5 years before the study. Exclusion criteria included exposure to glucocorticoids, CsA, mycophenolate mofetil or tacrolimus within 60 days before the study; established diagnosis of diabetes mellitus and/or treatment with insulin, insulin-sensitizing agents or peroxisome proliferator-activated receptor-g agonists; diagnosis of thalassemia and Fanconi anemia; serum creatinine levels 41.5 mg/100 ml; liver biopsy-proven chronic active hepatitis. All eligible patients seen in the LTFUC were approached and asked to participate. The recruitment period started on 1 December 2004 and ended on 3 January 2007. The first 10 subjects who satisfied the inclusion criteria during this period all consented to participate in the study and were thus enrolled.
Cancer diagnoses were ALL (n ¼ 7) and AML (n ¼ 3). The subjects' mean age was 8.7 ± 1.1 years at the time of the initial diagnosis of cancer (range 4.1-13.8 years), 13.0 ± 1.0 years at the time of TBI (range 8.6-19.6 years) and 24.0 ± 1.1 years at the time of the study (range 18.0-30.3 years). The endocrine complications for which these subjects had already been treated included hypergonadotropic hypogonadism (n ¼ 6), growth hormone (GH) deficiency (n ¼ 3) and hypothyroidism (n ¼ 1). No subject was receiving GH therapy at the time of the study, but six subjects were being treated with sex hormone replacement (four females, two males) and one subject was being treated with levothyroxine for hypothyroidism.
All the 10 study subjects were allogeneic HSCT recipients. Of the 10 study subjects, 5 had received cranial radiotherapy before HSCT at doses of 900-2400 cGy. All study subjects received hyperfractionated TBI as part of their conditioning regimen for HSCT as previously described.
9,10 TBI was delivered via a linear accelerator in 11 or 12 fractions of 125 cGy each at a dose rate of 8-20 cGy/min. The doses were administered three times daily for 3 days with two or three fractions on day 4 to a total dose of 1375 cGy (n ¼ 4) or 1500 cGy (n ¼ 6).
All male patients received an additional 400 cGy to the testes except one patient whose total testicular dose was 2600 cGy. Along with TBI, preparation for HSCT included high-dose chemotherapy using CY at 60 mg/kg/day for 2 consecutive days. CY was combined with another drug in eight subjects: thiotepa (n ¼ 4) or etoposide (n ¼ 4). None of the patients had evidence of chronic GVHD.
Methods
The study included a formal clinical assessment. Past medical and family histories were recorded and a physical exam was performed, including the measurement of height, weight, waist and hip circumference. We calculated body mass index (BMI) (weight (kg)/height (m) 2 ), weight to hip and waist to height ratios. These were compared to the risk categories defined by the World health Organization. 11 A single blood sample was drawn between 0800 hours and 0830 hours following a 12 h fast for the measurement of the plasma concentrations of glucose, insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, free fatty acids, high sensitivity C reactive protein (CRP), ferritin, insulin-like growth factor 1 (IGF-1), IGF-binding protein 3, IL6 and adiponectin. Impaired fasting glucose was defined by a value above 100 mg/100 ml. 12 The homeostasis model assessment (HOMA) and the quantitative insulin sensitivity check index (QUICKI) were calculated from fasting glucose and insulin levels and used to assess insulin resistance. Both indices have been shown to correlate significantly with the glucose clamp, and could provide some assessment of insulin sensitivity using a single fasting blood sample. [13] [14] [15] [16] HOMA values above 2.6 (75th percentile) and QUICKI values below 0.33 (25th percentile) were considered diagnostic of insulin resistance. 13 
Results

Clinical data
Of the 10 subjects included in the study, 3 (2 females, 1 male) were obese (BMI X30 kg/m 2 ) and 2 (both male) were overweight (BMI between 25 and 29.9 kg/m 2 ). All 10 subjects had evidence of excess abdominal fat, either by their waist to height ratio (n ¼ 6), waist to hip ratio (n ¼ 6) or both (n ¼ 4). All 10 subjects had normal systolic and diastolic blood pressures. Clinical findings are summarized in Table 1 .
Laboratory data
Of the 10 subjects included in the study, 5 were insulin resistant based on their HOMA and QUICKI indices, including 2 subjects with impaired fasting glucose. These five individuals included three obese subjects, one overweight subject and one individual whose BMI was borderline at 24.8 kg/m 2 . Another overweight subject had borderline HOMA and QUIKI values of 2.5 and 0.33, respectively. Of the five insulin-resistant subjects, three had been treated with cranial irradiation before TBI. One of these subjects was obese, one was overweight and the third had a borderline BMI of 24.8 kg/m 2 . Their cranial irradiation doses were 900, 1800 and 2400 cGy, respectively.
The following abnormal laboratory parameters were noted exclusively in subjects with insulin resistance: decreased IGF-1 (n ¼ 4); elevated CRP (n ¼ 2), decreased adiponectin (n ¼ 2); decreased HDL cholesterol (n ¼ 1). In addition, increased ferritin levels were noted in four subjects, two of whom were insulin resistant, and increased levels of IL6 in four subjects, two of whom were insulin resistant. Laboratory data are summarized in Table 2 .
Discussion
In this study, as in other studies, the predominant disorder of glucose homeostasis following childhood HSCT is insulin resistance. [3] [4] [5] [6] 17, 18 In one of the earliest reports on glucose metabolism in childhood HSCT recipients, Lorini et al. reported increased insulin secretion in subjects treated with HSCT when compared to healthy controls. Furthermore, insulin secretion and the insulin to glucose ratio were increased in patients treated with TBI when compared to HSCT recipients conditioned using other modalities. 4 Taskinen et al. diagnosed insulin resistance in 52% of childhood HSCT recipients using the oral glucose tolerance test. 17 In an updated report from this same group, out of 31 study subjects, 18 had hyperinsulinemia, 13 were glucose intolerant and 12 satisfied the diagnostic criteria for the metabolic syndrome. 18 Hoffmeister et al. described a higher than expected prevalence of type 2 diabetes, estimated at 9%, in leukemia survivors treated with HSCT. 5 In the study by Neville et al., childhood recipients of HSCT accounted for more than half of the cases of hyperinsulinemia, impaired glucose tolerance and diabetes mellitus. 6 In this study, four of the five subjects with insulin resistance were overweight or obese. All 10 subjects had Disorders of glucose homeostasis following TBI in childhood W Chemaitilly et al some evidence of abdominal obesity, which in itself represents a risk factor for insulin resistance. 19 These data differ from the results of others. In the study by Hoffmeister et al., only 2 of the 32 subjects diagnosed with type 2 diabetes were obese. 5 In the study by Neville et al., BMI measurements were similar between childhood cancer survivors and controls; however, abdominal obesity did emerge as a as an important independent risk factor for insulin resistance and impaired glucose tolerance following HSCT. 6 Along similar lines, a report from the Bone Marrow Transplantation Survivor Study on 1089 adult and pediatric HSCT recipients revealed a higher risk of diabetes mellitus, especially after TBI, even after adjustment for BMI when study subjects were compared to a control group composed of their siblings. 8 The latter study did not include a specific assessment of abdominal obesity. 8 It is important to note, however, that in this study three out of the five insulin-resistant subjects had received brain irradiation before HSCT, which in itself has been associated with overweight and/or obesity. 20, 21 TBI may impact on body fat distribution and insulin sensitivity indirectly by inducing GH deficiency. An increased incidence of GH deficiency after TBI in childhood has been reported in several studies. [22] [23] [24] [25] [26] In turn, GH deficiency has been associated with abdominal obesity, dyslipidemia, insulin resistance and the metabolic syndrome. 17, 18, 27 Out of the five insulin-resistant subjects in our cohort, two were diagnosed with GH deficiency during childhood and four had low IGF-1 levels at the time of the study.
Whether TBI could also impact on insulin resistance by directly altering the peripheral tissues involved in insulin action (skeletal muscle, adipose tissue, the liver) remains an open question. In this study, we looked at several factors known to affect insulin sensitivity and insulin action. We measured the plasma levels of adiponectin, an adipose tissue-derived protein known to have insulin-sensitizing effects. 28 Interestingly, the two study subjects who were among the most severely affected, with the highest BMI and highest degree of insulin resistance (one of them had impaired glucose tolerance), had low plasma levels of adiponectin. However, factors such as free fatty acids, IL6 and plasma concentrations of ferritin [29] [30] [31] did not demonstrate any clear associations with insulin resistance in our cohort.
This pilot study has several limitations. The TBI doses delivered to the study subjects using the hyperfractionated regimen were higher than doses generally delivered in the single-dose (800-1000 cGy) or fractionated (1200 cGy) regimens used for TBI at other institutions. Hyperfractionated TBI has nevertheless been associated with lower toxicity to normal tissue when compared to the other TBI regimens. 10 The small sample size may have resulted in our underestimating the association of insulin resistance with some of the metabolic parameters. In addition, assessment of insulin resistance using indices calculated from a single fasting blood sample may have resulted in an underestimation of the true prevalence of insulin resistance and impaired glucose tolerance. Exposure to brain irradiation before TBI may also be another confounding factor. Nonetheless, the study highlights the need for further investigation into the risk of insulin resistance in young adult survivors of childhood HSCT, who were exposed to TBI.
Conclusion
The predominant disorder of glucose homeostasis following childhood HSCT is insulin resistance, which appears to be associated with an increased BMI and increased abdominal obesity. Our preliminary data suggest that GH deficiency may play a role in the development of insulin resistance in this population.
